tirzepatide maker FDA says the weight-loss drug shortage is over Tirzepatide Weight Loss Injections &

Since its initial approval, it has seen expanded uses, new formulations, and dosage updates, further strengthening its role as a leading treatment for weight management and related conditions

Endocrinology 115 (6), 21762181

Head-to-head clinical data from the SURPASS/SURMOUNT trials shows tirzepatide at higher doses (10mg and 15mg) produced significantly greater weight loss than semaglutide 2.4mg , approximately 20.2% versus 13.7% over 72 weeks

Patients achieving goal weights may continue treatment indefinitely to maintain results, potentially at reduced doses

Overdose symptoms, particularly nausea and vomiting, can cause dehydration quickly